Study guide
10.1 Prescription Labels: Utah Minimum Elements, Controlled Substance & Opioid Warnings, and Special Labels
Utah MPJE Pharmacy Jurisprudence Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Utah Pharmacy Regulatory Framework, Facility Licensing & the PIC
1.1 DOPL, the Utah State Board of Pharmacy & the Sources of Utah Pharmacy Law 1.2 Federal vs. Utah Law: Following the Stricter Standard 1.3 Utah Pharmacy License Classes (A–E) & Facility Licensing 1.4 The Pharmacist-in-Charge (PIC): Duties, Self-Audits & Notifications 1.5 Facility Inspections, Ownership & Location Changes, Closing & Facility Discipline
2 Chapter 2: Pharmacist, Intern & Technician Licensure and Personnel
2.1 Pharmacist Licensure, the NAPLEX & Utah MPJE, and Licensure by Endorsement 2.2 License Renewal, Continuing Education & Reinstatement 2.3 Pharmacy Interns & Preceptors 2.4 Pharmacy Technicians, Technician Trainees & Supportive Personnel
3 Chapter 3: Unlawful & Unprofessional Conduct, Discipline, and Impairment
3.1 Unlawful Conduct, Criminal Penalties, Fines & the Disciplinary Process 3.2 Unprofessional Conduct, the APhA Code of Ethics & Utah's Conscience Law 3.3 Impairment, the Utah Professionals Health Program & Reinstatement
4 Chapter 4: Prescription Issuance, Prescriber Authority & Electronic Prescribing
4.1 Prescriber Scope of Authority in Utah 4.2 Required Prescription Elements, Oral & Faxed Orders, and Alterations 4.3 Mandatory Electronic Prescribing of Controlled Substances (EPCS) in Utah 4.4 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags
5 Chapter 5: Patient Counseling, Prospective DUR, Confidentiality & Records
5.1 Patient Counseling: The Offer, Who May Counsel & Delivered Prescriptions 5.2 Prospective Drug Utilization Review & Patient Medication Profiles 5.3 Confidentiality, HIPAA & Protected Health Information 5.4 Pharmacy Records, Retention Periods & Facility Operating Standards
6 Chapter 6: Expanded Practice: Collaboration, Pharmacist Prescribing & Drug Administration
6.1 Collaborative Pharmacy Practice, Drug Therapy Management & Administration of Drugs 6.2 Self-Administered Hormonal Contraception: Standing Order & Pharmacist Prescribing 6.3 Pharmacist Prescribing Under Utah Code § 58-17b-627: Tobacco Cessation, HIV PrEP/PEP, Fluoride & Epinephrine 6.4 Vaccine Administration: DOPL's Protocol, Delegation, Emergencies & USIIS Reporting
7 Chapter 7: Opioid Overdose Prevention, Emergency Refills & Returned or Donated Drugs
7.1 Naloxone & Opioid-Safety Laws in Utah 7.2 Emergency Refills, Combined Refills & Insulin Continuity 7.3 Returned Drugs, Consumer Disposal & the Charitable Prescription Drug Recycling Program
8 Chapter 8: Controlled Substance Schedules, Registration & Security in Utah
8.1 Controlled Substance Schedules: Federal CSA & Utah-Specific Scheduling 8.2 DEA Registration & Facility Licensing 8.3 Controlled Substance Storage & Physical Security
9 Chapter 9: Dispensing Controlled Substances & the Utah Controlled Substance Database
9.1 Schedule II Prescriptions: 30-Day Window, One-Month Supply, Multiple Prescriptions & the 7-Day Acute Limit 9.2 Schedule II Partial Fills, Emergency Oral Orders & Methadone Emergency Orders 9.3 Schedule III–V Prescriptions: Refill Limits, the 80% Rule & Controlled Substance Transfers 9.4 The Utah Controlled Substance Database (CSD)
10 Chapter 10: Dispensing Standards: Labeling, Substitution, Refills, Packaging, Product Integrity & OTC Products
10.1 Prescription Labels: Utah Minimum Elements, Controlled Substance & Opioid Warnings, and Special Labels 10.2 Drug Product Selection: Generic Equivalents, Therapeutically Similar Drugs & Interchangeable Biologics 10.3 Legend-Drug Prescription Validity, Refills & Transfers 10.4 Poison Prevention Packaging Act (PPPA) & Special Packaging 10.5 Drug Product Conditions That Prohibit Dispensing: Adulterated, Misbranded, Outdated, Recalled & Suspect Products 10.6 Nonprescription Products: OTC Labeling & Packaging, Pseudoephedrine, Iodine, Schedule V & Other Restricted OTC Sales
11 Chapter 11: Acquisition, Inventory, Loss, Distribution & Delivery
11.1 Ordering Schedule II Substances: DEA Form 222 & CSOS 11.2 Controlled Substance Inventories & Utah's Schedule II Perpetual Inventory 11.3 Theft, Significant Loss & Disposal of Controlled Substances 11.4 Drug Acquisition & Distribution, Office-Use Sales, and Delivering Prescriptions to Patients
12 Chapter 12: Compounding Standards, USP Chapters & Hazardous Drugs
12.1 Non-Sterile Compounding & USP <795> Standards 12.2 Sterile Compounding & USP <797> Standards 12.3 Hazardous Drug Handling & USP <800> Standards
13 Chapter 13: Institutional, Central Processing, Remote Dispensing, Specialty Outlets & Automation
13.1 Institutional Practice: Hospitals, Pharmaceutical Administration Facilities & Emergency Drug Kits 13.2 Centralized Prescription Processing, Telepharmacy & Remote Dispensing Pharmacies 13.3 Nuclear Pharmacies, Class E Outlets & Dispensing Medical Practitioners 13.4 Automated Pharmacy Systems, Quality Assurance & Pharmacy Audits
10.1 Prescription Labels: Utah Minimum Elements, Controlled Substance & Opioid Warnings, and Special Labels
Key Takeaways Explain This Topic AI
A Utah prescription label must show the pharmacy's name, address, and phone; the serial number; the fill date; the patient's name (or owner and species); the prescriber's name; directions and cautions; the drug name, amount, and strength; and the beyond-use date (Utah Code § 58-17b-602(5)).
When a Utah pharmacy dispenses a Schedule II or III opiate, the container or lid must carry the warning "Caution: Opioid. Risk of overdose and addiction" or DHHS-approved language (Utah Code § 58-37-112(4)).
Since January 1, 2024, a Utah pharmacy must offer naloxone counseling and dispensing when a single opioid prescription is 50 MME/day or more, or when an opioid and a benzodiazepine are dispensed within 30 days of each other.
Labels for compounded prescriptions must add the generic name and the quantity or concentration of each active ingredient; sterile parenterals also need the diluent, lot number, and the words "compounded preparation" (R156-17b-614a(2)).
Federal law requires the "Caution: Federal law prohibits the transfer of this drug" warning on Schedule II–IV prescription labels, but not on Schedule V (21 CFR 290.5).
Last updated: September 2026
10.1 Prescription Labels: Utah Minimum Elements, Controlled Substance & Opioid Warnings, and Special Labels
Blueprint item 3.5 covers labeling of dispensed drugs. Utah's rules are in § 58-17b-602(5)–(8) , § 58-37-112 , R156-17b-614a(2) , and several special-purpose provisions.
Minimum label elements (§ 58-17b-602(5)(a))
Every drug dispensed must have a securely affixed label showing at least:
- the name, address, and telephone number of the pharmacy ;
- the serial (prescription) number the pharmacy assigned;
- the filling date , or the last dispensing date ;
- the patient's name , or for an animal, the owner's name and the species ;
- the prescriber's name ;
- the directions for use and any cautionary statements in the prescription or otherwise needed;
the trade, generic, or chemical name, the amount dispensed, and the strength (for multiple-ingredient products with established names, those names may be used); and
the beyond-use date .
Exceptions and variations:
If the prescriber specifically directs that the drug name not appear, the drug name and strength are left off (§ 58-17b-602(7)).
Items 1–6 do not apply to containers of drugs that a health care provider administers at a pharmaceutical administration facility or a licensed hospital (§ 58-17b-602(5)(b)).
DOPL encourages, but does not require, including the condition being treated on the label, unless the prescriber or patient objects (§ 58-17b-602.5).
A substituted product must be labeled with the name of the drug actually dispensed (§ 58-17b-605(7)(b)).
Under expedited partner therapy , the patient's identifying information may be omitted from the partner's label (§ 58-1-501.3(4)).
Controlled substance labels (§ 58-37-112)
Controlled substances must be packaged and labeled as federal law requires. Only a pharmacist filling a prescription may alter, deface, or remove a manufacturer's label.
The dispensing label must show the pharmacy name and address, serial number, date of initial filling, prescription number, patient name (or owner and species), prescriber, and directions.
Schedule II and III opiates: affix the warning "Caution: Opioid. Risk of overdose and addiction" (or DHHS-approved language) to the container or lid .
Naloxone offer (since January 1, 2024): offer to counsel on the use and availability of an opiate antagonist, and offer to dispense one (on a prescription or under the standing order), when:
- a single opioid prescription is 50 MME/day or more ;
- an opioid is dispensed and the pharmacy dispensed a benzodiazepine to the patient in the previous 30 days ; or
a benzodiazepine is dispensed and the pharmacy dispensed an opioid to the patient in the previous 30 days.
Display DHHS's opioid informational pamphlet at the point of sale, if DHHS makes it available.
Federal CS transfer warning (21 CFR 290.5): "Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed" is required on Schedule II, III, and IV prescription labels. It is not required on Schedule V.
Compounded preparations (R156-17b-614a(2))
When dispensed to a patient, labels for compounded sterile and non-sterile preparations must include the § 58-17b-602 minimum information plus :
- the generic name ;
- the quantity or concentration of each active ingredient ; and
for sterile parenteral preparations, the diluent , the compounding record or lot number , and the phrase "compounded preparation."
Compounded or repackaged drugs sold to a practitioner for office administration must be labeled "for office use only" (§ 58-17b-624).
Special-purpose labels
Situation Label content
Hospital discharge in the multidose container used during the stay Patient name, drug name and strength, directions (if applicable), and pharmacy name and phone (§ 58-17b-602(6))
ED emergency supply or hospital discharge supply dispensed by a prescriber Prescriber name, facility name and phone, patient name, drug and strength, date given, directions, and beyond-use date (R156-17b-610.5(3); R156-17b-610.6(2))
- Insulin refill of an exhausted prescription " exhausted prescription " (R156-17b-612b(1)(d))
- Emergency refill under R156-17b-612(11) A § 58-17b-602 label
Charitable recycling program A label clearly showing the drug was dispensed under the program (R156-17b-901(6))
Federal labeling points
FDA side-effects statement (21 CFR Part 209): with each new and refill prescription, give patients the statement "Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088," on the label or cap, a sticker, the pharmacy leaflet, or the Medication Guide.
Medication Guides (21 CFR Part 208): must be given with specified drugs when dispensed to outpatients.
USP <17> recommends patient-centered label design: patient name, drug, and clear directions most prominent. It is a best-practice standard, not a Utah statute.
Scenario
A patient receives a first fill of hydrocodone/acetaminophen for 60 MME/day. The pharmacy already dispensed alprazolam to this patient two weeks ago. The label must carry the Utah opioid warning and the federal transfer caution. The pharmacy must offer naloxone counseling and dispensing, since both the 50 MME trigger and the opioid-benzodiazepine trigger apply.